Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2017
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2017
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2017, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.
Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 1, 4, 1, 10 and 1 respectively.
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2017, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.
Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 1, 4, 1, 10 and 1 respectively.
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
Adverum Biotechnologies Inc
Arrowhead Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
Cevec Pharmaceuticals GmbH
CSL Ltd
iBio Inc
Ionis Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Pharming Group NV
ProMetic Life Sciences Inc
Rezolute Inc
Shire Plc
Verseon Corp
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles
ADVM-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AROF-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATN-035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATN-249 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-7353 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icatibant acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-PKKLRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-PKKRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KVD-818 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KVD-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanadelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RZ-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones
Featured News & Press Releases
Nov 27, 2017: Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST for Prophylaxis of Hereditary Angioedema Attacks
Oct 27, 2017: BioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAIs 2017 Annual Scientific Meeting
Oct 26, 2017: Shire Receives European Approval for Label Extension of FIRAZYR (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Pediatric Patients
Oct 23, 2017: Shire to Present New Data on Icatibant Research At ACAAI 2017 Annual Scientific Meeting
Oct 23, 2017: Shire to Present New Data on Lanadelumab Research
Oct 17, 2017: AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor AB-602 Candidate for Treatment of HAE
Oct 02, 2017: Pharming Announces Positive Data from Pediatric Clinical Trial with RUCONEST
Sep 26, 2017: Verseon Developing Oral Treatment for Hereditary Angioedema
Sep 14, 2017: Shire Orphan Therapies receives CHMP positive opinion for Firazyr
Sep 11, 2017: Shires Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial
Sep 11, 2017: Pharming Announces Conclusion of FDA End of Phase 2 Interactions on RUCONEST for Prophylaxis of HAE
Sep 05, 2017: BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE
Aug 09, 2017: Berinert Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients
Aug 02, 2017: BioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks
Jul 26, 2017: Pharming Announces Publication of RUCONEST Prophylactic Data in The Lancet
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Adverum Biotechnologies Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Cevec Pharmaceuticals GmbH, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by iBio Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ProMetic Life Sciences Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Rezolute Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Shire Plc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Verseon Corp, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, H2 2017
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
Adverum Biotechnologies Inc
Arrowhead Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
Cevec Pharmaceuticals GmbH
CSL Ltd
iBio Inc
Ionis Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Pharming Group NV
ProMetic Life Sciences Inc
Rezolute Inc
Shire Plc
Verseon Corp
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles
ADVM-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AROF-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATN-035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATN-249 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-7353 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icatibant acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-PKKLRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-PKKRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KVD-818 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KVD-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanadelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RZ-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones
Featured News & Press Releases
Nov 27, 2017: Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST for Prophylaxis of Hereditary Angioedema Attacks
Oct 27, 2017: BioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAIs 2017 Annual Scientific Meeting
Oct 26, 2017: Shire Receives European Approval for Label Extension of FIRAZYR (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Pediatric Patients
Oct 23, 2017: Shire to Present New Data on Icatibant Research At ACAAI 2017 Annual Scientific Meeting
Oct 23, 2017: Shire to Present New Data on Lanadelumab Research
Oct 17, 2017: AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor AB-602 Candidate for Treatment of HAE
Oct 02, 2017: Pharming Announces Positive Data from Pediatric Clinical Trial with RUCONEST
Sep 26, 2017: Verseon Developing Oral Treatment for Hereditary Angioedema
Sep 14, 2017: Shire Orphan Therapies receives CHMP positive opinion for Firazyr
Sep 11, 2017: Shires Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial
Sep 11, 2017: Pharming Announces Conclusion of FDA End of Phase 2 Interactions on RUCONEST for Prophylaxis of HAE
Sep 05, 2017: BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE
Aug 09, 2017: Berinert Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients
Aug 02, 2017: BioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks
Jul 26, 2017: Pharming Announces Publication of RUCONEST Prophylactic Data in The Lancet
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Adverum Biotechnologies Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Cevec Pharmaceuticals GmbH, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by iBio Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ProMetic Life Sciences Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Rezolute Inc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Shire Plc, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Verseon Corp, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, H2 2017
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, H2 2017
List Of Figures
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
RELATED REPORTS
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials Review, H2, 2021
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials
View ReportHereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials Review, H1, 2021
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials Review, H1, 2021GlobalDatas clinical trial report, Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials
View ReportHereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials Review, H2, 2021
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials
View ReportHereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials Review, H1, 2021
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials Review, H1, 2021GlobalDatas clinical trial report, Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Global Clinical Trials
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
